Table 2 Medications at baseline
From: Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
Sulfonylureas (%) | 21 |
Biguanides (%) | 63 |
Alpha-GIs (%) | 10 |
Glinides (%) | 0 |
TZDs (%) | 16 |
DPP4 inhibitors (%) | 63 |
GLP1 receptor agonists (%) | 5 |
ACEIs (%) | 5 |
ARBs (%) | 37 |
Calcium channel blockers (%) | 32 |
Beta-blockers (%) | 5 |
Alpha-blockers (%) | 5 |
Diuretics (%) | 0 |
Statins (%) | 53 |
Fibrates (%) | 5 |
Anti-platelet agents (%) | 32 |